Monoclonal antibodies (mAbs) neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were the first antiviral drugs specifically developed for the treatment and prophylaxis of coronavirus disease 2019 (COVID-19) (1). Emergence of variants of concern (VOC) resistant to such antibodies on population level, however, limits their broad applicability. The Omicron variants, for example, are only neutralized by a small subset of monoclonal antibodies developed for the treatment of SARS-CoV-2 infections (2, 3). As more variants emerge, having a repertoire of monoclonal antibodies targeting different sites of the Spike protein may become useful. Therefore, we explored the prophylactic efficacy of two monoclonal antibodies targeting the receptor binding domain (RBD) of SARS-CoV-2 in a nonhuman primate model of SARS-CoV-2 infection. We additionally investigated their genetic barrier to resistance in vivo and in vitro.

The disease COVID-19 is caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). The virus was first identified at the beginning of 2020, and has since gone on to cause a pandemic. It is currently believed that SARS-CoV-2 is an example of a zoonosis.Throughout 2020, much of the world’s medical scientific community was devoted to developing a vaccine for SARS-CoV-2. To evaluate the effectiveness of new vaccines, both humoral and cell-mediated responses are measured in animal subjects. Identify the cell type that is involved in both responses, and explain its role in each.

The coronavirus disease 2019 (COVID-19) pandemic challenged the work-ings of human society, but in doing so, it advanced our understanding ofthe ecology and evolution of infectious diseases. Fluctuating transmissionof severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demon-strated the highly dynamic nature of human social behavior, often withoutgovernment intervention. Evolution of SARS-CoV-2 in the first two yearsfollowing spillover resulted primarily in increased transmissibility, while inthe third year, the globally dominant virus variants had all evolved substantialimmune evasion. The combination of viral evolution and the buildup of hostimmunity through vaccination and infection greatly decreased the realizedvirulence of SARS-CoV-2 due to the age dependence of disease severity. TheCOVID-19 pandemic was exacerbated by presymptomatic, asymptomatic,and highly heterogeneous transmission, as well as highly variable diseaseseverity and the broad host range of SARS-CoV-2. Insights and tools de-veloped during the COVID-19 pandemic could provide a stronger scientificbasis for preventing, mitigating, and controlling future pandemics.

To assess the extent of immune escape of the SARS-CoV-2 Omicron variant, we first mapped its mutations on the RBD and compared these regions with the binding epitopes of some previously reported antibodies (Lu et al., 2021; Yu et al., 2020; Figure S1). According to the spatial overlapping of antibody epitopes and viral mutations, the RBD-targeting antibodies can be grouped into three types: those that bind to the RBM, those that bind the cryptic epitopes hidden or partially hidden inside the trimeric interface, and antibodies that bind to lateral surface epitopes outside the trimeric interface (Figure 1A). This classification was comparable to a study of a large panel of SARS-CoV-2 antibodies, which classified epitopes into RBM, inner face, and outer face (Hastie et al., 2021), corresponding to our groups of RBM, cryptic epitopes, and lateral surface epitopes. Evidently, more mutations were involved in the epitopes of apex RBM-binding antibodies than the other two clusters (Figure 1B). To confirm this finding, we measured the binding and neutralization titer of plasma collected from 7 vaccine recipients who received three doses of inactivated SARS-CoV-2 vaccine. The average median binding titer (ED50) of serum declined by 12.8-fold for Omicron RBD, while the neutralizing potency (average median neutralizing titer, ID50) decreased by 5.1-fold against Omicron pseudovirus (Figures 1C, S2A, and S2B). Interestingly, we found that some vaccinees had high binding and neutralizing antibody titers against the wild-type (WT) SARS-CoV-2 but relatively low neutralization titers against the Omicron variant. To understand the underlying mechanism, we performed epitope binning by saturating the RBM of the SARS-CoV-2 RBD with ACE2, and then loaded plasma to allow the binding of non-RBM antibodies (Figures 1D, S2C, and S2D). The Spearman’s rank correlation test was applied to measure the potential relationship between ID50 with RBM- or non-RBM-binding antibodies. This analysis revealed a high correlation between the binding of non-RBM a

What was it about the COVID-19 virus that made it spread rapidly through the population and cause disease on a greater scale than other SARS related coronaviruses?Question 11AnswerMutations in the spike protein allowed it to specifically interact with the ACE2 receptor on lung cells. Also, the correct positioning of basic amino acids within the spike protein which could be cleaved was vital.Mutations in the spike protein allowed it to specifically interact with the ACE2 receptor on lung cellsThe correct positioning of basic amino acids in the spike protein which could be cleavedMutations in the spike protein allowed it to specifically interact with the ACE2 receptor on lung cells. Also, the correct positioning of acidic amino acids in the spike protein which could be cleaved was vital.

Severe acute respiratory syndrome (SARS) is an illness caused by a coronavirus.  Symptoms including a high fever, headaches, and body aches typically occur two to seven days after infection by the virus.  SARS is more serious in elderly patients.  This information suggests that the reproductive cycle of the SARS virus is-Responseslytic, because the virus causes respiratory illnesslytic, because the virus causes respiratory illnesslysogenic, because the virus is a coronaviruslysogenic, because the virus is a coronaviruslytic, because of the quick onset of symptoms after infectionlytic, because of the quick onset of symptoms after infectionlysogenic, because the virus primarily affects older people